Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 19/20 | 0.84 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.68 |
| ▸ | INSR | P06213 | 1/20 | 0.65 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.65 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.65 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12429488 | 0.91 | IGF1R (1.00) | IGF1RPTK2INSRMAPK8MAPK10 | |
| SCHEMBL12429376 | 0.91 | IGF1R (0.86) | IGF1RPTK2INSRMAPK8MAPK10 | |
| SCHEMBL13393598 | 0.85 | IGF1R (0.85) | IGF1RPTK2INSRMAPK8MAPK10 | |
| SCHEMBL11918997 | 0.84 | IGF1R (0.82) | IGF1RPTK2INSRMAPK8MAPK10 | |
| SCHEMBL12429321 | 0.84 | IGF1R (1.00) | IGF1RPTK2INSRMAPK8MAPK10 | |
| Gsk-1220512A SCHEMBL12429476 | 0.83 | IGF1R (1.00) | IGF1RINSRMAPK8MAPK10ALK | |
| SCHEMBL12429512 | 0.83 | IGF1R (0.85) | IGF1RINSRMAPK8MAPK10ALK | |
| SCHEMBL12429489 | 0.82 | IGF1R (1.00) | IGF1RINSRMAPK8MAPK10ALK | |
| SCHEMBL11919128 | 0.82 | PTK2 (0.70) | IGF1RPTK2INSRALK | |
| SCHEMBL12429545 | 0.81 | IGF1R (1.00) | IGF1RINSRMAPK8MAPK10ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210609-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2017-08-30 | — | — | EP | claimed |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-13 | — | — | US | disclosed |
| US-9273077-B2 | Phosphorus derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | IGF1R 543/4885PTK2 141/4885INSR 767/4885 |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | IGF1R 586/4885PTK2 75/4885INSR 985/4885 |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | IGF1R 543/4885PTK2 141/4885INSR 767/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | IGF1R 543/4885PTK2 141/4885INSR 767/4885 |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | IGF1R 526/4885PTK2 87/4885INSR 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.